Review




Structured Review

Sony anti-cd25 (bc96)
Anti Cd25 (Bc96), supplied by Sony, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25++bc96/pm38438084-265-41-46
Average 90 stars, based on 1 article reviews
anti-cd25 (bc96) - by Bioz Stars, 2026-09
90/100 stars

Images



Similar Products

90
Thermo Fisher anti-hu cd25 apc clone: bc96
α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, <t>CD25.</t> Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.
Anti Hu Cd25 Apc Clone: Bc96, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25/pmc12045076-66-29-34
Average 90 stars, based on 1 article reviews
anti-hu cd25 apc clone: bc96 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Thermo Fisher apc anti-human cd25 (clone bc96)
CD56 bright NK cells expanded in IL-2 and TGF-β1 exhibit regulatory functions in vitro (A) Method of NK cell isolation, PBMCs were stained with FITC conjugated antibodies for the following lineage markers: CD3, CD4, CD8α, CD14, CD15, CD19, CD20, TCRαβ, TCRδγ, CD33, CD34, CD203c, FCεr1α, CD79α, and CD138. NK were sorted as live CD56 bright CD16 − or CD56 dim CD16 + , and CCR6 − and CRTH2 − to exclude ILC2s and ILC3s. (B) Representative gating strategy to sort CD56 bright CD16 − NK cells and CD56 dim CD16 + NK cells from healthy PBMCs. (C) Fold expansion of NK cells after 19 days of in vitro culture in IL-2, IL-15, and IL-18 cytokines, or IL-2, TGF-β1, and anti-IFN-γ referred to as NK conv and NK TGF-β , respectively. (D) Representative and summary cytokine expression of CD56 bright NK conv and NK TGF- β at day 20 post-expansion, stimulated with phorbol 12-mystrate 13-acetate (PMA)/ionomycin for a duration of 6 h ( n = 7, 3). (E) Active TGF-β1 within supernatants of NK cells plated at 1 M/mL at D20 ( n = 14, 16). (F and G) Naive autologous CD4 + T cells were labeled with cell proliferation dye (CPD) for a short term 4-day culture with either NK conv ( n = 4) or NK TGF-β ( n = 6) with anti-CD3 and anti-CD28 antibodies. Suppression was measured by percent divided of the live CD3 + CD4 + CD56 − CD8 − in comparison to naive CD4 + T cells activated with anti-CD3 and anti-CD28 antibodies. Dashed line indicates 0 percent suppression. (H) Summary of CPD + HELIX-NP + and Annexin-V + K562 cells. Helix-NP + Annexin-V + indicates apoptotic cells ( n = 5, 6). (I) Expression of FOXP3 and <t>CD25</t> within co-cultures with NK cells ( n = 3–6). (J) Following 20 days co-culture of CD4 + T cells with IL-2 and TGF-β1-treated CD56 bright NK cells, CD25 + CD127 low/− T cells were sorted then co-cultured with CPD stained allogeneic naive T cells for 3 days ( n = 3, 4). Induced Tregs (iTregs) were generated using standard induction protocols of IL-2 and TGF-β1 ( n = 3, 4). Suppression as measured by percent divided of CD4 + CD3 + CPD + T cells. Asterisk indicates a significant difference, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. Significance was determined by Kruskal-Wallis test (C–E and G), (F) Mann-Whitney U test, and (I) Signed Wilcoxon-rank test. Data are represented as mean ± SEM (D and I) or median (E, F, H, and I) are shown.
Apc Anti Human Cd25 (Clone Bc96), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25/pmc11667056-47-0-6
Average 90 stars, based on 1 article reviews
apc anti-human cd25 (clone bc96) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-human cd25 (bc96)
CD56 bright NK cells expanded in IL-2 and TGF-β1 exhibit regulatory functions in vitro (A) Method of NK cell isolation, PBMCs were stained with FITC conjugated antibodies for the following lineage markers: CD3, CD4, CD8α, CD14, CD15, CD19, CD20, TCRαβ, TCRδγ, CD33, CD34, CD203c, FCεr1α, CD79α, and CD138. NK were sorted as live CD56 bright CD16 − or CD56 dim CD16 + , and CCR6 − and CRTH2 − to exclude ILC2s and ILC3s. (B) Representative gating strategy to sort CD56 bright CD16 − NK cells and CD56 dim CD16 + NK cells from healthy PBMCs. (C) Fold expansion of NK cells after 19 days of in vitro culture in IL-2, IL-15, and IL-18 cytokines, or IL-2, TGF-β1, and anti-IFN-γ referred to as NK conv and NK TGF-β , respectively. (D) Representative and summary cytokine expression of CD56 bright NK conv and NK TGF- β at day 20 post-expansion, stimulated with phorbol 12-mystrate 13-acetate (PMA)/ionomycin for a duration of 6 h ( n = 7, 3). (E) Active TGF-β1 within supernatants of NK cells plated at 1 M/mL at D20 ( n = 14, 16). (F and G) Naive autologous CD4 + T cells were labeled with cell proliferation dye (CPD) for a short term 4-day culture with either NK conv ( n = 4) or NK TGF-β ( n = 6) with anti-CD3 and anti-CD28 antibodies. Suppression was measured by percent divided of the live CD3 + CD4 + CD56 − CD8 − in comparison to naive CD4 + T cells activated with anti-CD3 and anti-CD28 antibodies. Dashed line indicates 0 percent suppression. (H) Summary of CPD + HELIX-NP + and Annexin-V + K562 cells. Helix-NP + Annexin-V + indicates apoptotic cells ( n = 5, 6). (I) Expression of FOXP3 and <t>CD25</t> within co-cultures with NK cells ( n = 3–6). (J) Following 20 days co-culture of CD4 + T cells with IL-2 and TGF-β1-treated CD56 bright NK cells, CD25 + CD127 low/− T cells were sorted then co-cultured with CPD stained allogeneic naive T cells for 3 days ( n = 3, 4). Induced Tregs (iTregs) were generated using standard induction protocols of IL-2 and TGF-β1 ( n = 3, 4). Suppression as measured by percent divided of CD4 + CD3 + CPD + T cells. Asterisk indicates a significant difference, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. Significance was determined by Kruskal-Wallis test (C–E and G), (F) Mann-Whitney U test, and (I) Signed Wilcoxon-rank test. Data are represented as mean ± SEM (D and I) or median (E, F, H, and I) are shown.
Anti Human Cd25 (Bc96), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25/pm39269653-89-30-43
Average 90 stars, based on 1 article reviews
anti-human cd25 (bc96) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-human cd25-pe clone: bc96

Anti Human Cd25 Pe Clone: Bc96, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25/pmc11533540-2-0-5
Average 90 stars, based on 1 article reviews
anti-human cd25-pe clone: bc96 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-cd25-pe (bc96)

Anti Cd25 Pe (Bc96), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25/pmc11449757-112-10-28
Average 90 stars, based on 1 article reviews
anti-cd25-pe (bc96) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

95
fluidigm anti cd194 l291h4 152sm standard biotools anti cd25 bc96

Anti Cd194 L291h4 152sm Standard Biotools Anti Cd25 Bc96, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/Anti-CD3+(UCHT1)-170Er/10__7554_slash_elife__95494__3-402-92-96
Average 95 stars, based on 1 article reviews
anti cd194 l291h4 152sm standard biotools anti cd25 bc96 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

90
Thermo Fisher anti-cd25-apc bc96

Anti Cd25 Apc Bc96, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/us12016909-527-10-13
Average 90 stars, based on 1 article reviews
anti-cd25-apc bc96 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

95
fluidigm anti human cd25 bc96 153eu

Anti Human Cd25 Bc96 153eu, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/Maxpar+Direct+Immune+Profiling+Assay/pmc11126817-14-0-5
Average 95 stars, based on 1 article reviews
anti human cd25 bc96 153eu - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

90
Thermo Fisher alexa fluor‐488‐labeled anti‐cd25(clone: bc96

Alexa Fluor‐488‐Labeled Anti‐Cd25(clone: Bc96, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/Alexa+Fluor+488+Goat+Anti-Mouse+SFX+Kit/pm38658734-489-74-77
Average 90 stars, based on 1 article reviews
alexa fluor‐488‐labeled anti‐cd25(clone: bc96 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sony anti-cd25 (bc96)

Anti Cd25 (Bc96), supplied by Sony, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd25+bc96/anti+cd25++bc96/pm38438084-265-41-46
Average 90 stars, based on 1 article reviews
anti-cd25 (bc96) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

doi: 10.1016/j.biopha.2024.117265

Figure Lengend Snippet: α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.

Article Snippet: The master mix was prepared using anti-human CD3 FITC (Clone: UCHT1; Biolegend, Cat#300406), Anti-Human CD4 PE (Clone: OKT4; eBioscience Cat#4337556), Anti-Hu CD8a PE-Cyanine 7 (Clone: SK1; eBioscience Cat#2066348) and Anti-Hu CD25 APC (Clone: BC96; eBioscience Cat#1946588) antibodies.

Techniques: Expressing, Activation Assay, Marker, Flow Cytometry, Control

CD56 bright NK cells expanded in IL-2 and TGF-β1 exhibit regulatory functions in vitro (A) Method of NK cell isolation, PBMCs were stained with FITC conjugated antibodies for the following lineage markers: CD3, CD4, CD8α, CD14, CD15, CD19, CD20, TCRαβ, TCRδγ, CD33, CD34, CD203c, FCεr1α, CD79α, and CD138. NK were sorted as live CD56 bright CD16 − or CD56 dim CD16 + , and CCR6 − and CRTH2 − to exclude ILC2s and ILC3s. (B) Representative gating strategy to sort CD56 bright CD16 − NK cells and CD56 dim CD16 + NK cells from healthy PBMCs. (C) Fold expansion of NK cells after 19 days of in vitro culture in IL-2, IL-15, and IL-18 cytokines, or IL-2, TGF-β1, and anti-IFN-γ referred to as NK conv and NK TGF-β , respectively. (D) Representative and summary cytokine expression of CD56 bright NK conv and NK TGF- β at day 20 post-expansion, stimulated with phorbol 12-mystrate 13-acetate (PMA)/ionomycin for a duration of 6 h ( n = 7, 3). (E) Active TGF-β1 within supernatants of NK cells plated at 1 M/mL at D20 ( n = 14, 16). (F and G) Naive autologous CD4 + T cells were labeled with cell proliferation dye (CPD) for a short term 4-day culture with either NK conv ( n = 4) or NK TGF-β ( n = 6) with anti-CD3 and anti-CD28 antibodies. Suppression was measured by percent divided of the live CD3 + CD4 + CD56 − CD8 − in comparison to naive CD4 + T cells activated with anti-CD3 and anti-CD28 antibodies. Dashed line indicates 0 percent suppression. (H) Summary of CPD + HELIX-NP + and Annexin-V + K562 cells. Helix-NP + Annexin-V + indicates apoptotic cells ( n = 5, 6). (I) Expression of FOXP3 and CD25 within co-cultures with NK cells ( n = 3–6). (J) Following 20 days co-culture of CD4 + T cells with IL-2 and TGF-β1-treated CD56 bright NK cells, CD25 + CD127 low/− T cells were sorted then co-cultured with CPD stained allogeneic naive T cells for 3 days ( n = 3, 4). Induced Tregs (iTregs) were generated using standard induction protocols of IL-2 and TGF-β1 ( n = 3, 4). Suppression as measured by percent divided of CD4 + CD3 + CPD + T cells. Asterisk indicates a significant difference, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. Significance was determined by Kruskal-Wallis test (C–E and G), (F) Mann-Whitney U test, and (I) Signed Wilcoxon-rank test. Data are represented as mean ± SEM (D and I) or median (E, F, H, and I) are shown.

Journal: iScience

Article Title: Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cells

doi: 10.1016/j.isci.2024.111416

Figure Lengend Snippet: CD56 bright NK cells expanded in IL-2 and TGF-β1 exhibit regulatory functions in vitro (A) Method of NK cell isolation, PBMCs were stained with FITC conjugated antibodies for the following lineage markers: CD3, CD4, CD8α, CD14, CD15, CD19, CD20, TCRαβ, TCRδγ, CD33, CD34, CD203c, FCεr1α, CD79α, and CD138. NK were sorted as live CD56 bright CD16 − or CD56 dim CD16 + , and CCR6 − and CRTH2 − to exclude ILC2s and ILC3s. (B) Representative gating strategy to sort CD56 bright CD16 − NK cells and CD56 dim CD16 + NK cells from healthy PBMCs. (C) Fold expansion of NK cells after 19 days of in vitro culture in IL-2, IL-15, and IL-18 cytokines, or IL-2, TGF-β1, and anti-IFN-γ referred to as NK conv and NK TGF-β , respectively. (D) Representative and summary cytokine expression of CD56 bright NK conv and NK TGF- β at day 20 post-expansion, stimulated with phorbol 12-mystrate 13-acetate (PMA)/ionomycin for a duration of 6 h ( n = 7, 3). (E) Active TGF-β1 within supernatants of NK cells plated at 1 M/mL at D20 ( n = 14, 16). (F and G) Naive autologous CD4 + T cells were labeled with cell proliferation dye (CPD) for a short term 4-day culture with either NK conv ( n = 4) or NK TGF-β ( n = 6) with anti-CD3 and anti-CD28 antibodies. Suppression was measured by percent divided of the live CD3 + CD4 + CD56 − CD8 − in comparison to naive CD4 + T cells activated with anti-CD3 and anti-CD28 antibodies. Dashed line indicates 0 percent suppression. (H) Summary of CPD + HELIX-NP + and Annexin-V + K562 cells. Helix-NP + Annexin-V + indicates apoptotic cells ( n = 5, 6). (I) Expression of FOXP3 and CD25 within co-cultures with NK cells ( n = 3–6). (J) Following 20 days co-culture of CD4 + T cells with IL-2 and TGF-β1-treated CD56 bright NK cells, CD25 + CD127 low/− T cells were sorted then co-cultured with CPD stained allogeneic naive T cells for 3 days ( n = 3, 4). Induced Tregs (iTregs) were generated using standard induction protocols of IL-2 and TGF-β1 ( n = 3, 4). Suppression as measured by percent divided of CD4 + CD3 + CPD + T cells. Asterisk indicates a significant difference, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. Significance was determined by Kruskal-Wallis test (C–E and G), (F) Mann-Whitney U test, and (I) Signed Wilcoxon-rank test. Data are represented as mean ± SEM (D and I) or median (E, F, H, and I) are shown.

Article Snippet: APC anti-human CD25 (clone BC96) , eBioscience , Cat#17-0259-42; RRID: AB_1582219.

Techniques: In Vitro, Cell Isolation, Staining, Expressing, Labeling, Comparison, Co-Culture Assay, Cell Culture, Generated, MANN-WHITNEY

Journal: iScience

Article Title: Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cells

doi: 10.1016/j.isci.2024.111416

Figure Lengend Snippet:

Article Snippet: APC anti-human CD25 (clone BC96) , eBioscience , Cat#17-0259-42; RRID: AB_1582219.

Techniques: Recombinant, Staining, Selection, Software

Journal: STAR Protocols

Article Title: Protocol for mapping T cell activation using single-cell RNA-seq

doi: 10.1016/j.xpro.2024.103409

Figure Lengend Snippet:

Article Snippet: Anti-human CD25-PE (clone: BC96) , eBioscience , Cat #12-0259-42; 1:200.

Techniques: Recombinant, Cell Culture, Transferring, Software

Journal: iScience

Article Title: Peripheral immunophenotyping reveals lymphocyte stimulation in healthy women living with hereditary breast and ovarian cancer syndrome

doi: 10.1016/j.isci.2024.109882

Figure Lengend Snippet:

Article Snippet: anti-human-CD25 (BC96) - 153Eu , Standard BioTools , Cat. No.: 201325.

Techniques: Recombinant, DNA Extraction, Staining, Blocking Assay, Mass Cytometry, Software